🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This phase II trial studies how well acalabrutinib works in treating patien...
Status
Active Not Recruiting
Location
Moffitt Cancer Center
Start Date
2020-12-11
Trial ID
NCT04198922
Treatments Being Tested
This is a phase II trial, with the aim of developing a chemotherapy-free re...
Status
Active Not Recruiting
Location
Department of Hematology X, Odense University Hospital
Start Date
2021-12-15
Trial ID
NCT05214183
Treatments Being Tested
This study is to determine the response to acalabrutinib in patients with c...
Status
Completed
Location
Research Site
Start Date
2015-01-12
Trial ID
NCT02337829
Treatments Being Tested
This phase II trial compares three chemotherapy regimens consisting of bend...
Status
Active Not Recruiting
Location
Anchorage Associates in Radiation Medicine
Start Date
2019-12-13
Trial ID
NCT04115631
Treatments Being Tested
This phase II trial investigates the how well acalabrutinib and obinutuzuma...
Status
Active Not Recruiting
Location
M D Anderson Cancer Center
Start Date
2020-08-25
Trial ID
NCT04505254
Treatments Being Tested
This phase II trial studies how well acalabrutinib and venetoclax with or w...
Status
Recruiting
Location
M D Anderson Cancer Center
Start Date
2020-07-29
Trial ID
NCT04169737
Treatments Being Tested
CLL2-BAAG is a prospective, open-label, multicenter phase-II trial to evalu...
Status
Completed
Location
Universitätsklinik Köln
Start Date
2019-01-14
Trial ID
NCT03787264
Treatments Being Tested
This phase Ib/II trial studies the side effects of acalabrutinib and duveli...
Status
Withdrawn
Location
Multiple Locations
Start Date
2022-07-01
Trial ID
NCT04836832
Treatments Being Tested
This phase II trial is to evaluate the effects of acalabrutinib in combinat...
Status
Recruiting
Location
Fred Hutch/University of Washington Cancer Consortium
Start Date
2023-05-31
Trial ID
NCT04941716
To characterize the safety profile of acalabrutinib in subjects with relaps...
Status
Completed
Location
Research Site
Start Date
2014-08-07
Trial ID
NCT02112526
Treatments Being Tested